share_log

Insiders Were the Biggest Winners as Anhui Huaren Health Pharmaceutical Co., Ltd.'s (SZSE:301408) Market Cap Grew by CN¥508m Last Week

Insiders Were the Biggest Winners as Anhui Huaren Health Pharmaceutical Co., Ltd.'s (SZSE:301408) Market Cap Grew by CN¥508m Last Week

内部人士是最大赢家,安徽华人健康药品有限公司(SZSE:301408)市值在上周增长了50800万元人民币。
Simply Wall St ·  12/12 18:52

Key Insights

关键见解

  • Anhui Huaren Health Pharmaceutical's significant insider ownership suggests inherent interests in company's expansion
  • The largest shareholder of the company is Jiale He with a 50% stake
  • Institutions own 13% of Anhui Huaren Health Pharmaceutical
  • 安徽华仁健康药业的重大内部所有权表明公司扩张的固有利益
  • 该公司的最大股东是何佳乐,持有50%的股份
  • 机构持有安徽华仁健康药业 13% 的股份

To get a sense of who is truly in control of Anhui Huaren Health Pharmaceutical Co., Ltd. (SZSE:301408), it is important to understand the ownership structure of the business. We can see that individual insiders own the lion's share in the company with 57% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

要了解谁真正控制了安徽华仁健康药业有限公司(SZSE: 301408),了解该业务的所有权结构非常重要。我们可以看到,个别内部人士拥有公司的大部分股份,所有权为57%。也就是说,如果股票上涨,该集团将受益最大(如果出现低迷,则损失最大)。

Clearly, insiders benefitted the most after the company's market cap rose by CN¥508m last week.

显然,上周该公司的市值上涨了50800万元人民币之后,内部人士受益最大。

Let's take a closer look to see what the different types of shareholders can tell us about Anhui Huaren Health Pharmaceutical.

让我们仔细看看不同类型的股东能告诉我们关于安徽华仁健康药业的哪些信息。

big
SZSE:301408 Ownership Breakdown December 12th 2024
SZSE: 301408 所有权明细 2024 年 12 月 12 日

What Does The Institutional Ownership Tell Us About Anhui Huaren Health Pharmaceutical?

关于安徽华仁健康药业,机构所有权告诉我们什么?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

机构投资者通常将自己的回报与常用指数的回报进行比较。因此,他们通常会考虑收购包含在相关基准指数中的大型公司。

We can see that Anhui Huaren Health Pharmaceutical does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Anhui Huaren Health Pharmaceutical's historic earnings and revenue below, but keep in mind there's always more to the story.

我们可以看到,安徽华仁健康药业确实有机构投资者;他们持有该公司很大一部分股票。这表明专业投资者有一定的信誉。但是我们不能仅仅依靠这个事实,因为机构有时会像所有人一样进行不良投资。当多家机构拥有一只股票时,总是存在处于 “拥挤交易” 的风险。当这样的交易出错时,多方可能会竞相快速出售股票。对于没有增长历史的公司,这种风险更高。你可以在下面看到安徽华仁健康药业的历史收益和收入,但请记住,故事总是有更多内容。

big
SZSE:301408 Earnings and Revenue Growth December 12th 2024
SZSE: 301408 2024年12月12日收益和收入增长

We note that hedge funds don't have a meaningful investment in Anhui Huaren Health Pharmaceutical. The company's largest shareholder is Jiale He, with ownership of 50%. This implies that they have majority interest control of the future of the company. Alibaba Health Information Technology Limited is the second largest shareholder owning 7.5% of common stock, and Jialun He holds about 6.9% of the company stock. Jialun He, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors.

我们注意到,对冲基金没有对安徽华仁健康药业进行有意义的投资。该公司的最大股东是何佳乐,拥有50%的所有权。这意味着他们对公司的未来拥有多数权益控制权。阿里巴巴健康信息技术有限公司是第二大股东,拥有7.5%的普通股,何佳伦持有公司约6.9%的股份。第三大股东何佳伦也恰好拥有董事会成员的头衔。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.

虽然研究公司的机构所有权可以为你的研究增加价值,但研究分析师的建议以更深入地了解股票的预期表现也是一种很好的做法。据我们所知,分析师对该公司没有报道,因此它可能被忽视了。

Insider Ownership Of Anhui Huaren Health Pharmaceutical

安徽华仁健康药业的内部所有权

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

尽管内部人员的确切定义可能是主观的,但几乎所有人都认为董事会成员是内部人士。公司管理层对董事会的回答,董事会应代表股东的利益。值得注意的是,有时高层管理人员自己也在董事会中。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常认为内部所有权是一件好事。但是,在某些情况下,这使得其他股东更难要求董事会对决策负责。

Our most recent data indicates that insiders own the majority of Anhui Huaren Health Pharmaceutical Co., Ltd.. This means they can collectively make decisions for the company. That means they own CN¥3.0b worth of shares in the CN¥5.3b company. That's quite meaningful. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.

我们的最新数据显示,内部人士拥有安徽华仁健康药业有限公司的大部分股份。这意味着他们可以共同为公司做出决策。这意味着他们拥有这家价值30元人民币的公司股份。这很有意义。很高兴看到这样的投资水平。你可以在这里查看这些内部人士最近是否在买入。

General Public Ownership

普通公有制

The general public, who are usually individual investors, hold a 17% stake in Anhui Huaren Health Pharmaceutical. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

公众通常是个人投资者,持有安徽华仁健康药业17%的股份。尽管这个群体不一定能做主,但它肯定会对公司的运作方式产生真正的影响。

Private Company Ownership

私人公司所有权

Our data indicates that Private Companies hold 5.2%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

我们的数据显示,私营公司持有公司5.2%的股份。私营公司可能是关联方。有时,内部人士通过控股私营公司而对上市公司拥有权益,而不是以个人身份拥有权益。尽管很难得出任何宽泛的结论,但值得注意的是,这是一个需要进一步研究的领域。

Public Company Ownership

上市公司所有权

It appears to us that public companies own 7.5% of Anhui Huaren Health Pharmaceutical. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.

在我们看来,上市公司拥有安徽华仁健康药业7.5%的股份。这可能是战略利益,两家公司可能有相关的商业利益。可能是他们已经消失了。这一裁定可能值得进一步调查。

Next Steps:

后续步骤:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks for example - Anhui Huaren Health Pharmaceutical has 2 warning signs we think you should be aware of.

尽管值得考虑拥有公司的不同群体,但还有其他因素更为重要。以风险为例-安徽华仁健康药业有两个警告信号,我们认为您应该注意。

Of course this may not be the best stock to buy. So take a peek at this free free list of interesting companies.

当然,这可能不是最值得购买的股票。因此,请看看这份有趣的公司的免费免费清单。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后日期的12个月期间。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?担心内容吗?直接联系我们。或者,发送电子邮件给编辑组(网址为)simplywallst.com。
Simply Wall St 的这篇文章本质上是笼统的。我们仅使用公正的方法提供基于历史数据和分析师预测的评论,我们的文章并非旨在提供财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不会考虑最新的价格敏感型公司公告或定性材料。华尔街只是没有持有上述任何股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发